ESMO Supporter 2018

Found 1 Presentation For Request "1295P"

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology Poster Display session

1295P - Treatment of Advanced Basal Cell Carcinoma With Sonidegib: Duration of Response and Quality of Life Evaluation From BOLT

Presentation Number
Lecture Time
12:45 - 12:45
  • Michael R. Migden (Houston, US)
Hall A3 - Poster Area Networking Hub, ICM M√ľnchen, Munich, Germany
12:45 - 13:45



For patients with advanced basal cell carcinoma (BCC), including those with locally advanced BCC (laBCC) and metastatic BCC (mBCC), hedgehog pathway inhibitors (HPIs) are a treatment option. Sonidegib is an HPI approved for use in patients with advanced BCC (Switzerland and Australia) and laBCC (USA and EU), based on data from the BOLT study (NCT01327053). Here we report the duration of response (DOR) at 42 months and quality of life (QoL) results at the 12- and 30-month analyses from BOLT.


BOLT was a multicenter, randomized, double-blind, phase 2 trial that evaluated sonidegib in treatment-naïve patients with mBCC (n = 36) or laBCC (n = 194) who were not amenable to curative surgery or radiation therapy. Patients were randomized 1:2 to either 200 mg or 800 mg PO QD, and data analyses were performed at 6, 12, 18, 30, and 42 months. The primary endpoint was objective response rate (ORR) and a key secondary endpoint included DOR as assessed by central review. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and the associated Head and Neck Cancer Module 35 (EORTC H&N35).


At the 42-month analysis, the median DOR was 26.1 months in laBCC patients treated with sonidegib 200 mg vs 23.3 months in patients treated with 800 mg. The ORR was higher in the 200 mg group vs the 800 mg group (Table). In mBCC patients, the median DOR was 24 months for sonidegib 200 mg and not estimable for the 800 mg group. The ORR was lower in the 200 mg group vs the 800 mg group (Table). During the course of treatment, the QoL for these patients was analyzed, and the majority of patients in both dosage groups had maintenance of or improvement in QoL relative to baseline.

ORR in sonidegib-treated patients with advanced BCC

200 mg800 mg200 mg800 mg
n = 66n = 128n = 13n = 23
ORR %5646817
Complete Response, n (%)3 (4.5)2 (1.6)00
Partial Response, n (%)34 (51.5)57 (44.5)1 (7.7)4 (17.4)


Data from the 42-months analysis demonstrated that patients receiving sonidegib had a long duration of response. Results from the 12- and 30-month analyses show maintenance and improvement in QoL consistent with that of the primary data observed in BOLT.

Clinical trial identification

NCT01327053 CLDE225A2201.

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.


Novartis Pharmaceuticals Corporation.

Editorial Acknowledgement

Medical writing support provided by Adriana Vela, PhD, Medical Exchange International, LLC, New York, NY.


M.R. Migden: Honorarium for advisory boards and consulting: Regeneron, Sun Pharmaceuticals, Novartis.